Eggers Verena, Fügener Katja, Hein Ortrud Vargas, Rommelspacher Hans, Heyes Melvyn P, Kox Wolfgang J, Spies Claudia D
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Charité, Campus Mitte, Humboldt University Berlin, Schumannstrasse 20/21, 10117, Berlin, Germany.
Intensive Care Med. 2004 Aug;30(8):1544-51. doi: 10.1007/s00134-004-2285-6. Epub 2004 Apr 27.
To investigate antibiotic-mediated release of tumour necrosis factor (TNF)-alpha and norharman in patients with hospital-acquired pneumonia with and without additional septic encephalopathy.
Prospective observational study with a retrospective post hoc analysis.
Surgical intensive care unit (ICU) at a university hospital.
Thirty-seven patients were consecutively included (9 patients with hospital-acquired pneumonia, 11 patients with hospital-acquired pneumonia and septic encephalopathy, 17 control patients) in the study. Pneumonia was defined according to the criteria of the American Thoracic Society.
Patients received cephalosporins for antibiotic treatment of hospital-acquired pneumonia. Blood samples were taken before, immediately after and 4 h after application of cephalosporins.
Of the pneumonia patients, 55% developed septic encephalopathy. ICU stay, complications and mortality were significantly increased. An increased release of TNF-alpha was immediately seen in all pneumonia patients after antibiotics compared to controls, whereas the level did not differ between patients with and without septic encephalopathy. Norharman was significantly increased in pneumonia patients 4 h after antibiotic treatment, in tendency more enhanced in the pneumonia patients without encephalopathy.
Patients with hospital-acquired pneumonia and septic encephalopathy had a significantly longer ICU stay with higher mortality rate compared to patients with hospital-acquired pneumonia alone. Antibiotic-mediated TNF-alpha release may induce the kynurenine pathway. TNF-alpha activates indolamine-2,3-dioxygenase with neurotoxic quinolinic acid as the end product. Norharman seems to counteract this mechanism and seems to play a role in neuroprotection. The worse outcome of patients with encephalopathy expresses the need to investigate protective factors and mechanisms.
研究在有或无额外脓毒症性脑病的医院获得性肺炎患者中,抗生素介导的肿瘤坏死因子(TNF)-α和去甲哈尔满的释放情况。
前瞻性观察研究及回顾性事后分析。
一所大学医院的外科重症监护病房(ICU)。
本研究连续纳入了37例患者(9例医院获得性肺炎患者、11例医院获得性肺炎合并脓毒症性脑病患者、17例对照患者)。肺炎根据美国胸科学会的标准定义。
患者接受头孢菌素治疗医院获得性肺炎。在应用头孢菌素前、用药后即刻及用药后4小时采集血样。
肺炎患者中,55%发生了脓毒症性脑病。ICU住院时间、并发症及死亡率显著增加。与对照组相比,所有肺炎患者在使用抗生素后即刻可见TNF-α释放增加,而有或无脓毒症性脑病的患者之间该水平无差异。抗生素治疗后4小时,肺炎患者去甲哈尔满显著增加,无脑病的肺炎患者增加趋势更明显。
与仅患有医院获得性肺炎的患者相比,医院获得性肺炎合并脓毒症性脑病的患者ICU住院时间显著更长,死亡率更高。抗生素介导的TNF-α释放可能诱导犬尿氨酸途径。TNF-α激活吲哚胺-2,3-双加氧酶,最终产物为具有神经毒性的喹啉酸。去甲哈尔满似乎可抵消这一机制,且似乎在神经保护中发挥作用。脑病患者预后较差表明有必要研究保护因素及机制。